Trilla-Fuertes, Lucía
Gámez-Pozo, Angelo
Maurel, Joan
Garcia-Carbonero, Rocio
Capdevila, Jaume
G-Pastrián, Laura
Mendiola, Marta
Peña, Cristina
López-Vacas, Rocío
Cuatrecasas, Miriam
García-Alfonso, Pilar
Ramos-Ruiz, Ricardo
Llorens, Carlos
Ghanem, Ismael
Conill, Carles
Heredia-Soto, Victoria
Campos-Barros, Ángel
Fresno Vara, Juan Ángel
Feliu, Jaime
Funding for this research was provided by:
Ministerio de Economía y Competitividad (DI-15-07614)
Article History
Received: 6 May 2020
Accepted: 11 March 2021
First Online: 1 April 2021
Competing interests
: AG-P and JAFV are shareholders of Biomedica Molecular Medicine SL. LT-F is an employee of Biomedica Molecular Medicine SL. JC has a scientific consultancy role (speaker and advisory roles) at Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, ITM, Sirlex and Merck Serono. There were research grants from Novartis, Pfizer, Astrazeneca, Advanced Accelerator Applications, Eisai and Bayer. IG has received honoraria and/or travel expenses from Roche, Sanofi, Merck, Servier, Amgen and Sirtflex, and for advisory role from Merck and Sanofi. JF has received consulting and advisory honoraria from Amgen, Ipsen, Eissai, Merck, Roche and Novartis; research funding from Merck, and travel and accommodation expenses from Amgen and Servier. The other authors declare no conflicts of interests.